Myoscint moves closer to approval:
This article was originally published in Clinica
The US FDA's Cardiovascular and Renal Drugs Advisory Committee has recommended approval for Centocor's heart attack imaging agent, Myoscint. Mallinckrodt Medical already distributes Myoscint in Europe and a product licence application is under review in Japan. Centocor will market the imaging agent, an (111-)In-labelled anti-myosin heavy chain antibody, in the US.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.